Top Markets
Coin of the day
Chordia Therapeutics Inc. Chordia Therapeutics Inc.

Chordia Therapeutics Inc.

190A
Rank in Stocks #26480
Chordia Therapeutics Inc., a biotech company, engages in research and... Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.
Share Price
$0.53499835
Market Cap
$40.24M
Change (1 day)
2.50%
Change (1 year)
-58.07%
Country
JP
Trade Chordia Therapeutics Inc. (190A)

Category

P/B ratio for Chordia Therapeutics Inc. (190A)
P/B ratio as of 2026 TTM: 0
According to Chordia Therapeutics Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Chordia Therapeutics Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
3.7087 -
US